Psilocybin Cancer Research Results

PSB, Psilocybin: Click to Expand ⟱
Features:

Psilocybin — a naturally occurring psychedelic tryptamine alkaloid and phosphorylated prodrug of psilocin (4-hydroxy-N,N-dimethyltryptamine). It is formally classified as a serotonergic psychedelic and psychoactive indole alkaloid. Standard abbreviation: PSB; active metabolite: psilocin (PSI). Psilocybin occurs naturally in certain Psilocybe and related mushroom species and can also be manufactured synthetically for clinical research. Its principal pharmacological activity involves serotonin 5-HT2A receptor agonism and modulation of neuroplasticity-associated pathways. Clinical research focuses on major depression, treatment-resistant depression, anxiety, and cancer-associated psychological distress. Its role in oncology is supportive rather than directly antineoplastic.

Primary mechanisms (ranked):

  1. Serotonin 5-HT2A receptor agonism: Psilocin activates cortical 5-HT2A receptors, engaging Gq/11-linked signaling and modifying cortical network activity, perception, cognition, and emotional processing.
  2. BDNF/TrkB neuroplasticity signaling: Psilocin can facilitate endogenous BDNF-dependent TrkB signaling, promoting synaptic plasticity and potentially contributing to sustained antidepressant effects.
  3. ERK and mTOR-associated synaptic remodeling: Downstream neurotrophic signaling supports dendritic spine formation, synaptic reorganization, and activity-dependent neuronal adaptation.
  4. Glutamatergic signaling modulation: Cortical serotonergic activation modifies excitatory neurotransmission and neural network connectivity, potentially facilitating psychological and behavioral adaptation.
  5. Intracellular calcium signaling: 5-HT2A-associated Gq/PLC/IP3 signaling can increase intracellular Ca2+ mobilization and influence neuronal excitability and downstream signaling.
  6. Emotional processing and network reorganization: Changes in cortical network connectivity and affective processing may contribute to reductions in depressive symptoms, anxiety, and existential distress when combined with psychological support.

Bioavailability / PK relevance: Oral psilocybin is rapidly dephosphorylated to psilocin, which is systemically absorbed and crosses the blood-brain barrier. Reported psilocin oral bioavailability is approximately 50–55%, although absolute bioavailability estimates remain limited. The terminal half-life is approximately 1.2–4.7 hours. Psilocin undergoes glucuronidation and oxidative metabolism, including formation of 4-hydroxyindole-3-acetic acid. Clinical research commonly employs controlled single-dose administration, frequently 25 mg synthetic psilocybin, with structured psychological support.

In-vitro vs systemic exposure relevance: Psilocin is pharmacologically active at relatively low receptor-binding concentrations, and some experimentally observed neuronal signaling effects occur at concentrations relevant to systemic exposure. However, cell-culture findings at micromolar concentrations cannot automatically be extrapolated to human plasma or tumor exposure. Psilocybin itself is a prodrug; direct in-vitro studies must distinguish psilocybin from psilocin. No clinically validated antitumor concentration or systemic anticancer exposure target has been established.

Clinical evidence status: RCT evidence supports investigational psilocybin-assisted treatment for depression and cancer-associated psychological distress. Small randomized cancer trials and subsequent clinical studies report rapid and potentially sustained improvements in depression, anxiety, and quality of life. Psilocybin remains investigational and is not an established cancer-directed therapy. Clinical evidence does not demonstrate tumor regression, improved progression-free survival, or improved overall survival attributable to psilocybin.

Safety and clinical constraints: Acute adverse effects include anxiety, altered perception, nausea, headache, transient tachycardia, and increased blood pressure. Important concerns include susceptibility to psychosis or mania, psychiatric destabilization, cardiovascular risk, and interactions with serotonergic or psychoactive medications. Supervised administration, patient screening, psychological preparation, and clinical monitoring are central to studied treatment protocols. Psilocybin is a controlled substance and is not an approved routine prescription treatment in Canada; access is subject to applicable research and special-access regulations.

Psilocybin Mechanisms and Clinical Relevance

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Serotonin 5-HT2A / Gq Signaling Not established ↑ 5-HT2A activation in responsive neurons P Altered cortical signaling, perception, and emotional processing Principal established receptor mechanism of psilocin. No demonstrated cancer-selective therapeutic activity.
2 BDNF / TrkB Neuroplasticity Not established ↑ BDNF-dependent TrkB signaling (model-dependent) R/G ↑ Synaptic plasticity and neuronal adaptation Psilocin facilitates endogenous BDNF signaling in experimental models. TrkB effects may be partially independent of 5-HT2A activation. Clinical mechanistic contribution remains under investigation.
3 ERK / mTOR Synaptic Remodeling Not established ↑ ERK/mTOR-associated signaling (model-dependent) R/G ↑ Dendritic remodeling and synaptic connectivity Observed in preclinical neuronal systems. These pathways should not be interpreted as anticancer mTOR inhibition.
4 Glutamate / Cortical Excitability Not established ↔ Glutamatergic activity (context-dependent) P/R Modification of excitatory neurotransmission and cortical network activity 5-HT2A activation can increase glutamate release, but net neuronal excitation varies by cell type and circuit.
5 PLC / IP3 / Ca2+ Signaling Not established ↑ Intracellular Ca2+ signaling in responsive neurons P Receptor-mediated calcium mobilization and neuronal signaling Gq-coupled 5-HT2A activation engages PLC and IP3-dependent calcium release. Direction and magnitude depend on neuronal subtype.
6 Neuronal Structural Plasticity Not established ↑ Dendritic spine formation and remodeling (model-dependent) G Potentially persistent alterations in neuronal connectivity Supported by preclinical cortical-neuron studies. Functional clinical relevance remains incompletely characterized.
7 Functional Brain Network Connectivity Not established ↔ Network connectivity and integration (context-dependent) P/G Altered network organization and emotional processing Human neuroimaging supports changes in functional connectivity. Effects are region-, time-, and measurement-dependent.
8 Depression / Anxiety / Existential Distress Not applicable ↓ Depressive and anxiety symptoms in clinical responders G Supportive oncology and psychiatric symptom improvement Supported by randomized human trials, including patients with cancer. Clinical outcomes rather than cellular signaling measurements.
9 ROS / NRF2 / Oxidative Stress Not established Not established as a principal mechanism — No validated therapeutic redox mechanism Insufficient evidence for a reproducible, clinically relevant ROS or NRF2-mediated anticancer effect.
10 Apoptosis / Cell Proliferation Not established Not established — No demonstrated selective tumor cytotoxicity Psilocybin should not be classified as an established apoptosis-inducing or antiproliferative anticancer compound.
11 Radiosensitization / Chemosensitization Not established Not established — No validated treatment-sensitizing effect Human studies involving cancer primarily measure psychiatric and quality-of-life outcomes, not enhanced tumor response.
12 Clinical Translation Constraint No established anticancer exposure target Acute psychoactive and cardiovascular effects; psychiatric screening required P/G Supervised dosing and restricted clinical deployment Rapid conversion to psilocin, short systemic half-life, variable psychological response, controlled-substance status, and limited oncology-specific trials constrain translation.

TSF: P: 0–30 min   R: 30 min–3 hr   G: >3 hr



Scientific Papers found: Click to Expand⟱
9120- PSB,    Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
- Trial, Var, NA
antiD↑, ANXi↓, Dose↝, Mood↑, QoL↑,
9121- PSB,    Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
- Trial, Var, NA
ANXA1↓, antiD↑, QoL↑,
9122- PSB,    Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial
- Trial, Var, NA
antiD↑, ANXi↓, Dose↝,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Immune & Inflammatory Signaling(tgid=16) ⓘ

ANXA1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 2,  

Functional Outcomes(tgid=23) ⓘ

antiD↑, 3,   ANXi↓, 2,   Mood↑, 1,   QoL↑, 2,  
Total Targets: 6

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:514  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page